CN101516397B - 用campath-1h治疗多发性硬化(ms) - Google Patents
用campath-1h治疗多发性硬化(ms) Download PDFInfo
- Publication number
- CN101516397B CN101516397B CN2007800341485A CN200780034148A CN101516397B CN 101516397 B CN101516397 B CN 101516397B CN 2007800341485 A CN2007800341485 A CN 2007800341485A CN 200780034148 A CN200780034148 A CN 200780034148A CN 101516397 B CN101516397 B CN 101516397B
- Authority
- CN
- China
- Prior art keywords
- treatment
- campath
- days
- treatment cycle
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Abstract
Description
Claims (12)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84425106P | 2006-09-13 | 2006-09-13 | |
US60/844,251 | 2006-09-13 | ||
EP06090169.1 | 2006-09-14 | ||
EP06090169 | 2006-09-14 | ||
PCT/EP2007/008084 WO2008031626A1 (en) | 2006-09-13 | 2007-09-11 | Treatment of multiple sclerosis (ms) with campath-1h |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100864372A Division CN102652832A (zh) | 2006-09-13 | 2007-09-11 | 用campath-1h治疗多发性硬化(ms) |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101516397A CN101516397A (zh) | 2009-08-26 |
CN101516397B true CN101516397B (zh) | 2012-05-30 |
Family
ID=39887242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800341485A Active CN101516397B (zh) | 2006-09-13 | 2007-09-11 | 用campath-1h治疗多发性硬化(ms) |
Country Status (2)
Country | Link |
---|---|
US (2) | US9498528B2 (zh) |
CN (1) | CN101516397B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
SI2130044T1 (sl) | 2007-02-16 | 2017-03-31 | Genzyme Corporation | Postopek prepoznavanja tveganja motnje ščitnice |
US20120058082A1 (en) * | 2009-05-13 | 2012-03-08 | Genzyme Corporation | Methods and compositions for treatment |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
US20150039337A1 (en) * | 2013-07-31 | 2015-02-05 | Elwha Llc | Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period |
US9940683B2 (en) | 2013-07-31 | 2018-04-10 | Elwha Llc | Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period |
TW201841653A (zh) * | 2017-04-21 | 2018-12-01 | 美商建新公司 | 以抗-cd52抗體治療多發性硬化症 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120766A (en) * | 1991-12-04 | 2000-09-19 | Hale; Geoffrey | CDW52-specific antibody for treatment of multiple sclerosis |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4012360A (en) * | 1973-12-03 | 1977-03-15 | Ciba-Geigy Corporation | Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
CN1245156C (zh) * | 1993-02-22 | 2006-03-15 | 美国生物科学有限公司 | 用于体内传送生物制品的方法及用于该方法的组合物 |
US5739686A (en) * | 1996-04-30 | 1998-04-14 | Naughton; Michael J. | Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection |
TWI332943B (en) * | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
US6924312B2 (en) * | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
AU2002360696A1 (en) | 2001-12-21 | 2003-07-30 | Ilex Oncology, Inc. | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
TWI330079B (en) * | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
ATE552276T1 (de) | 2003-11-01 | 2012-04-15 | Merck Patent Gmbh | Modifizierter anti-cd52-antikörper |
DK1781604T3 (da) * | 2004-06-23 | 2013-09-16 | Synta Pharmaceuticals Corp | Bis(thio-hydrazid-amid)-salte til behandling af cancere |
US20060142393A1 (en) * | 2004-09-16 | 2006-06-29 | Sherman Matthew L | Bis(thio-hydrazide amides) for treatment of hyperplasia |
EP1827410A2 (en) * | 2004-11-19 | 2007-09-05 | Synta Pharmaceuticals Corporation | Bis(thio-hydrazide amides) for increasing hsp70 expression |
WO2006124736A2 (en) * | 2005-05-16 | 2006-11-23 | Synta Pharmaceuticals Corp. | Synthesis of bis(thio-hydrazide amide) salts |
EP1940375A1 (en) * | 2005-08-16 | 2008-07-09 | Synta Pharmaceuticals Corporation | Bis(thio-hydrazide amide) formulation |
WO2007143174A2 (en) | 2006-06-01 | 2007-12-13 | The Regents Of The University Of California | Combination therapy method and formulation |
US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
ES2917882T3 (es) | 2006-09-13 | 2022-07-12 | Alcafleu Man Gmbh & Co Kg | Tratamiento de esclerosis múltiple (MS) con Campath-1H |
SI2130044T1 (sl) | 2007-02-16 | 2017-03-31 | Genzyme Corporation | Postopek prepoznavanja tveganja motnje ščitnice |
-
2007
- 2007-09-10 US US11/900,211 patent/US9498528B2/en active Active
- 2007-09-11 CN CN2007800341485A patent/CN101516397B/zh active Active
-
2012
- 2012-12-21 US US13/724,958 patent/US20130108625A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120766A (en) * | 1991-12-04 | 2000-09-19 | Hale; Geoffrey | CDW52-specific antibody for treatment of multiple sclerosis |
Non-Patent Citations (1)
Title |
---|
COX AMANDA.Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.《EUROPEAN JOURNAL OF IMMUNOLOGY》.2005,第35卷(第11期), * |
Also Published As
Publication number | Publication date |
---|---|
US20130108625A1 (en) | 2013-05-02 |
US20080267954A1 (en) | 2008-10-30 |
US9498528B2 (en) | 2016-11-22 |
CN101516397A (zh) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101516397B (zh) | 用campath-1h治疗多发性硬化(ms) | |
Tullman | A review of current and emerging therapeutic strategies in multiple sclerosis | |
JP2019167385A (ja) | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 | |
WO2017205101A1 (en) | Methods for treatment of refractory generalized myasthenia gravis | |
RU2574979C2 (ru) | Лечение рассеянного склероза (рс) | |
AU2007296857B2 (en) | Treatment of multiple sclerosis (MS) with Campath-1H | |
TWI565475B (zh) | 多發性硬化症(ms)之治療 | |
Kuhelj et al. | Open-label Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in Relapsing MS and Primary Progressive MS | |
AU2016204844A1 (en) | Treatment of multiple sclerosis (MS) with Campath-1H | |
Boiko et al. | Contemporary Algorithms for the Diagnosis and Treatment of Multiple Sclerosis Based on Individual Assessment of Patients’ Status | |
AU2013206718A1 (en) | Treatment of multiple sclerosis (MS) with Campath-1H | |
JP2023537751A (ja) | オクレリズマブで多発性硬化症を治療するための方法 | |
Mallucci | SWITCHING THERAPIES ANALYSIS IN MULTIPLE SCLEROSIS PATIENTS | |
TW202330030A (zh) | 用satralizumba治療中樞神經系統(cns)之脫髓鞘疾病 | |
Skuza et al. | P. 1.066 The interaction between selective sigmaligands and uncompetitive NMDA receptor antagonists in the forced swimming test in rats | |
Cree et al. | Pilot Trial of Low Dose Naltrexone and Quality of Life in MS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: EERKAFU MANAGEMENT LIMITED PARTNERSHIP Free format text: FORMER OWNER: SCHERING PHARMA CO., LTD. Effective date: 20100520 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: BERLIN, GERMANY TO: WALTERSDORF, GERMANY |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100520 Address after: German Walters Dov Applicant after: Genzyme Corp Co-applicant after: Genzyme Corp. Address before: Berlin Applicant before: Schering AG Co-applicant before: Genzyme Corp. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1136773 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1136773 Country of ref document: HK |